Severe asthma and the impact of biologicals on patients’ everyday life
Client: This study was financially supported by AstraZeneca BV, The Hague (D3250R00063) and executed in cooperation with the institute for Medical Technology Assessment (iMTA), Rotterdam.
A QUALitative study to explore the Impact of severe, eosinophilic asthma and Treatment – specifically the use of biologicals – on patients’ everyday life (QUALITy)
In this study we have explored the everyday life of patients with severe asthma in relation to the use of biologicals, using benralizumab as case in point. The main motivation for this exploration was the current lack of empirical insights into the everyday experiences of patients living with severe asthma and using biologicals. To contribute to this knowledge, we have asked two main questions: 1) How do patients with severe asthma experience their daily life? and 2) How do patients with severe asthma experience the care they receive, and specifically the use of benralizumab, within the context of their daily life? We have approached these questions through a mixed-method qualitative study in the Netherlands using a targeted review of available international literature, an analysis of existing patient-stories (ego-documents), two interviews with healthcare professionals and ten interviews with patients suffering from severe asthma. Conceptually we have focused our analysis on exploring patients’ experiences of the burden of disease and burden of treatment for severe asthma and the impact biologicals have on these experiences.
This study was financially supported by AstraZeneca BV, The Hague (D3250R00063) and executed in cooperation with the institute for Medical Technology Assessment (iMTA), Rotterdam. Runtime is 2019-2020.
Bert de Graaff, PhD, & Hester van de Bovenkamp, PhD